Akero Therapeutics (AKRO) Insider Trading & Ownership $31.16 -0.61 (-1.92%) (As of 11/26/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Akero Therapeutics (NASDAQ:AKRO) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage7.94%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$2.83 MNumber OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$22.73 M Get AKRO Insider Trade Alerts Want to know when executives and insiders are buying or selling Akero Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address AKRO Insider Buying and Selling by Quarter Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Akero Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/15/2024Catriona YaleInsiderSell9,061$27.73$251,261.53 11/1/2024Andrew ChengCEOSell108,366$31.73$3,438,453.18 11/1/2024Catriona YaleInsiderSell15,485$32.62$505,120.70 11/1/2024Jonathan YoungCOOSell50,716$31.57$1,601,104.12 10/30/2024Catriona YaleInsiderSell4,515$32.53$146,872.95 10/18/2024Andrew ChengCEOSell63,539$31.53$2,003,384.67 Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out? (Ad)Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?Click Here For Your Free Guide10/16/2024Andrew ChengCEOSell24,992$31.14$778,250.88 10/14/2024Catriona YaleInsiderSell6,136$30.03$184,264.08 10/14/2024Jonathan YoungCOOSell40,000$30.15$1,206,000.00 10/1/2024Jonathan YoungCOOSell10,000$28.18$281,800.00 9/20/2024Catriona YaleInsiderSell5,500$27.65$152,075.00 9/18/2024Catriona YaleInsiderSell3,871$27.56$106,684.76 9/16/2024Catriona YaleInsiderSell2,485$27.52$68,387.20 9/10/2024Andrew ChengCEOSell1,738$26.18$45,500.84 9/10/2024Catriona YaleInsiderSell637$26.18$16,676.66 9/10/2024Jonathan YoungCOOSell568$26.18$14,870.24 9/10/2024William Richard WhiteCFOSell639$26.18$16,729.02 8/26/2024Catriona YaleInsiderSell5,200$27.51$143,052.00 8/26/2024William Richard WhiteCFOSell75,159$27.21$2,045,076.39 8/23/2024Catriona YaleInsiderSell8,851$27.53$243,668.03 8/1/2024Jonathan YoungCOOSell5,000$26.75$133,750.00 7/24/2024William Richard WhiteCFOSell139,083$26.98$3,752,459.34 7/16/2024William Richard WhiteCFOSell34,811$28.04$976,100.44 7/1/2024Jonathan YoungCOOSell5,000$23.40$117,000.00 6/11/2024Andrew ChengCEOSell7,894$22.64$178,720.16 6/11/2024Catriona YaleInsiderSell2,825$22.64$63,958.00 6/11/2024Jonathan YoungCOOSell2,516$22.64$56,962.24 6/11/2024Patrick LamyVPSell569$22.64$12,882.16 6/11/2024William Richard WhiteCFOSell2,831$22.64$64,093.84 6/3/2024Jonathan YoungCOOSell5,000$19.29$96,450.00 5/1/2024Jonathan YoungCOOSell5,000$20.15$100,750.00 4/1/2024Jonathan YoungCOOSell5,000$24.38$121,900.00 3/4/2024Andrew ChengCEOSell75,000$32.87$2,465,250.00 3/4/2024Catriona YaleInsiderSell20,646$35.49$732,726.54 12/27/2023Jonathan YoungCOOSell5,414$24.00$129,936.00 12/14/2023Andrew ChengCEOSell1,628$20.76$33,797.28 12/14/2023Catriona YaleInsiderSell597$20.76$12,393.72 12/14/2023Jonathan YoungCOOSell543$20.76$11,272.68 12/14/2023William Richard WhiteCFOSell611$20.76$12,684.36 12/11/2023Andrew ChengCEOSell7,405$20.02$148,248.10 Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out? (Ad)Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?Click Here For Your Free Guide12/8/2023Andrew ChengCEOSell12,873$20.01$257,588.73 12/8/2023G. Walmsley GrahamDirectorBuy100,000$19.83$1,983,000.00 11/30/2023G. Walmsley GrahamDirectorBuy50,000$16.90$845,000.00 (Data available from 1/1/2013 forward) AKRO Insider Trading Activity - Frequently Asked Questions Who is on Akero Therapeutics's Insider Roster? The list of insiders at Akero Therapeutics includes Andrew Cheng, Catriona Yale, G. Walmsley Graham, Jonathan Young, Patrick Lamy, Seth Loring Harrison, Skorpios Trust, Timothy Rolph, Tomas J. Heyman, and William Richard White. Learn more on insiders at AKRO. What percentage of Akero Therapeutics stock is owned by insiders? 7.94% of Akero Therapeutics stock is owned by insiders. Learn more on AKRO's insider holdings. Which Akero Therapeutics insiders have been buying company stock? The following insider purchased AKRO shares in the last 24 months: G. Walmsley Graham ($11,281,700.00). How much insider buying is happening at Akero Therapeutics? Insiders have purchased a total of 350,000 AKRO shares in the last 24 months for a total of $11,281,700.00 bought. Which Akero Therapeutics insiders have been selling company stock? The following insiders have sold AKRO shares in the last 24 months: Andrew Cheng ($20,424,788.80), Catriona Yale ($4,806,002.24), Jonathan Young ($5,494,401.72), Patrick Lamy ($12,882.16), Seth Loring Harrison ($521,080.94), Skorpios Trust ($71,166,000.00), Timothy Rolph ($4,396,872.44), Tomas J. Heyman ($1,421,420.00), and William Richard White ($8,124,830.47). How much insider selling is happening at Akero Therapeutics? Insiders have sold a total of 2,889,101 Akero Therapeutics shares in the last 24 months for a total of $116,368,278.77 sold. Akero Therapeutics Key ExecutivesDr. Andrew Cheng M.D. (Age 57)Ph.D., President, CEO & Director Compensation: $1.04MDr. Jonathan M. Young J.D. (Age 54)Ph.D., Co-Founder, Executive VP, COO & Secretary Compensation: $672.35kDr. Timothy Rolph (Age 70)Co-Founder & Chief Scientific Officer Compensation: $722.32kMr. William R. White J.D. (Age 51)Executive VP, CFO, Treasurer & Head of Corporate Development Compensation: $678.06kMs. Catriona Yale (Age 52)Executive VP & Chief Development Officer Compensation: $678.06k11 recent tradesMr. Scott A. Gangloff (Age 50)Chief Technical Officer Mr. David West J.D.Vice President of LegalMr. John J. Schembri (Age 62)Vice President & Head of Finance Mr. Patrick Lamy (Age 51)Senior Vice President of Commercial Strategy 1 recent trades More Insider Trading Tools from MarketBeat Related Companies Nuvalent Insider Selling Elanco Animal Health Insider Selling Lantheus Insider Selling Blueprint Medicines Insider Selling Cytokinetics Insider Selling Viking Therapeutics Insider Selling Krystal Biotech Insider Selling TG Therapeutics Insider Selling Avidity Biosciences Insider Selling BridgeBio Pharma Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:AKRO) was last updated on 11/27/2024 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
